Mylan brand logo |
Mylan has been under fire during the past several years due to periodically raising the price of their trusted EpiPen product. They have been selling in a monopolistic market for several years. They have taken advantage of this situation in order to better their company with disregard for customers. Currently, the EpiPen is protected by a patent approved by the FDA. Meaning, no other company is allowed to produce a similar product, for it will be pulled from the market by the FDA. This has happened once, and even with the FDA protecting their market, they have continued to increase their product's price. David Whitrap, a spokesman for Express Scripts, said, "What we’re seeing from Mylan now is indicative of how many pharmacy companies negotiate during a momentary monopoly they price as high as they can for as long as they can" (nytimes.com). They knew the patent was expiring soon, and the company put the lives of many in danger by being greedy. The controversy obviously revolves around the price hike. When Mylan first acquired the EpiPen it was selling for around $124 for a package of two. To squeeze the expiring patent of a little more profit, they raised the price to over $600. This has been ongoing, meaning it was not $124 to $600 over night; it has happened over the several years Mylan has sold the EpiPen. Families who require these tools to keep their children safe are required to use old products as they cannot afford to replace them. What's worse, is Mylan knows that the EpiPen themselves expire only after one year, whether they are used or not. They have increased the price of a life-saving product that they know people are going to continuously purchase.
Stakeholders
Child using an EpiPen, a life-changing item for those with extreme allergies |
Individualism is one of four ethical theories that will be used to evaluate how ethically Mylan acted. Individualism, also known as the Economic Model of Responsibility, is a frame of mind that evaluates a company's action based on how it benefits the company. "It is the aim and the responsibility of businesses to maximize their profits" (Salazar 17). This ideology was first posed by Milton Friedman, the famous economist. The only constraint given by Friedman, is that all actions must comply with the law. Just this year, Mylan reported revenues of $9.36 billion and net income of $847 million for their fiscal year ending December 31, 2015. Compared to Fiscal year 2013, they earned revenues of $6.85 billion and net income of $626 million; there is evidence to show that the price hike has lead to an increase in revenue as well as profit (Annual Report). It maximized profits and did not have to mistreat its employees in doing so. Stakeholders such as patients and families were treated unfairly, however that is not a factor in individualism. It was ethical when simply taking into account the two key factors of individualism: 1) it maximizes profit and 2) it does so legally.
Utilitarianism
The EpiPen, well known to people who suffer from severe allergies |
Kantianism
Virtue theory is the last of the four philosophies and also happens to be the oldest. It was introduced by ancient Greek philosopher, Aristotle, as a means to "analyze actions within a virtue theory framework by asking whether the actions under consideration embody or advance virtues or not" (Salazar 23). He developed this framework by establishing four pillars for his theory: courage, honesty, temperance, and justice. Courage has to do with the company's level of risk-taking whether they uphold right ideas and actions. One may argue the company took a risk when they raised the price of their product, but it was not to uphold right ideas. Honesty refers to the company's trustworthiness in agreements. As said previously, they have not been honest as they lied about the EpiPen's profit. Temperance applies to a company's expectations and desires. It is fair to say that it was unreasonable for Mylan to expect their customers to pay more than four times what they normally paid. Justice examines if the company engages in hard work, quality products, good ideas, and fair practices. Mylan employees work had, produce quality goods, and brainstorm excellent ideas, however, they were not fair in carrying them out. They may have been courageous for the wrong reasons, but they were dishonest, misguided, and unfair.
Justified Ethical Evaluation
Mylan has acted in a manner that has negatively affected the ones who rely on the EpiPen. To make matters worse, the dilemma may have been avoidable from the beginning. It makes it must more unfortunate that Mylan chose the action that did not fully take into account the health of others. With a little more research, Mylan could have studied the effects of different price levels. The most obvious aspect is Mylan should have set it not as high. The company already has a near monopoly of the industry, so they don't have to worry about loss of sales to competitors. Of course, it is the nature of business for a company to set the highest price that they can, but it is ethics that helps determine what is too high. They could have researched the demographics of the EpiPen consumer base. By collecting data of various regions, they could have an idea of how many people could afford a certain price and how many could not. Also, the FDA is slightly at fault for letting it get out of hand. They are a government agency established to protect the citizens. They not only let Mylan get away with the price increases, but also ensure they were able to do so as the only product on the market.
Action Plan
Heather Bresch, CEO of Mylan |
Currently, Mylan is facing much pressure from the community to remedy their recent price hikes. Mylan has to go about this carefully as they want to remain profitable and remain the market leader when the patent expires. Mylan exposed many of their stakeholders into danger ever since the price increase. The lack of consideration for the lives of patients has caused major problems for the community. Mylan's first goal should be to fix these problems they have caused, and then address the company's motives. Their current mission statement is "At Mylan, we are committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine" (mylan.com). The recent scandal has undermined some of what they said they would do, and would require a new statement going forward. A good mission statement to revamp the company image would be something along the lines of "We promise to reasonably supply 7 billion people with high quality medicine in order to secure a healthy future for the world."
With the patent expiring soon, Mylan should consider an action plan that protects Mylan's future. The first and most important action Mylan should do is lower the price of the EpiPen. The next action should be to work with insurance companies to offer higher rebates and other deals to help pay for the medicine. Also, it would benefit Mylan to establish a donation of charity fund for the lower class who may not be able to afford EpiPens even at a reasonable price. Mylan absolutely has to reduce the price in order to pull themselves out of this dilemma. It was absurd for them to raise the price to such ridiculous levels in the first place and the population is acting accordingly. Also, when the patent ends, if they are still at their $600 price level as a cheaper generic enters the market, they will lose most of their market share. In regards to insurance companies, these are the businesses that Mylan relies on for a majority of their profit. The insurance company attempts to cover the cost up to a certain point. If Mylan can make a deal where the insurance companies pay more but buy in bulk and distribute to their clients, a mid-level price around $250 may be reasonable. Lastly, there will always be unfortunate families who require these tools but are too impoverished to buy it even at the original $124 price. Mylan can set up donations to help regain the trust of their longtime customers after years of scandal and dishonesty.
In order to prevent this from happening in the future, I think the introduction of competition will act as a natural barrier. Mylan was mainly only able to carry this out cause there were no consequences. The reason was to increase profit, and if they try this again with a generic on the market, then they will lose profit. Going forward, the only employee who should be penelized is Heather Bresch. Many have called for her to step down; this is a common move for a CEO to make after a scandal. Even if she does not want to step down, it becomes necessary for her to at least reduce her compensation by the 600% that she received for the price hikes; the company cannot endorse unethical behavior. Marketing becomes an important aspect when trying to fix ethical issues. The company has to issue a formal apology to its customers and promise to think about their well-being in the future. Mylan needs to try to regain the trust of patients. They can make deals with doctors to have them hand out brochures about the benefits of Mylan and the EpiPen. Mylan lost sight of the true reason they are a company: to promote the health of the population. With the actions and marketing plans being implemented, the company can grow and form a better ethical standard. They will regain the trust of their consumers and build stonger relationships while remaining profitable.Written By: Kanan Patel
"500,000 Petitions Delivered to Mylan Headquarters in Protest of EpiPen Price Hike." Wpxi News. N.p., n.d. Web. http://www.wpxi.com/news/500000-petitions-delivered-to-mylan-headquarters-in-protest-of-epipen-price-hike/433058945
"Annual Report." Mylan N.V. -. N.p., n.d. Web. 16 Nov. 2016 http://apps.shareholder.com/sec/viewerContent.aspx?companyid=ABEA-2LQZGT&docid=11180036
"Mission Statement." Mylan- Seeing Is Believing. N.p., n.d. Web.
https://www.mylan.com/en/careers/life-at-mylan
Pollack, Andrew. "Mylan Raised EpiPen’s Price Before the Expected Arrival of a Generic." The New York Times. The New York Times, 25 Aug. 2016. Web. 16 Nov. 2016. http://www.nytimes.com/2016/08/25/business/mylan-raised-epipens-price-before-the-expected-arrival-of-a-generic.html?_r=0
Popken, Ben. "Mylan CEO Salary Rose by 600 Percent as EpiPen Price Rose 400 Percent." NBC News. N.p., n.d. Web. 16 Nov. 2016. http://www.nbcnews.com/business/consumer/mylan-execs-gave-themselves-raises-they-hiked-epipen-prices-n636591
"Reference for Business." Mylan Laboratories Inc. - Company Profile, Information, Business Description, History, Background Information on Mylan Laboratories Inc. N.p., n.d. Web. 16 Nov. 2016. http://www.referenceforbusiness.com/history2/71/Mylan-Laboratories-Inc.html
Robertson, Sally. "Drug Patents and Generic Pharmaceutical Drugs." News-Medical.net. N.p., 08 Sept. 2014. Web. 16 Nov. 2016. http://www.news-medical.net/health/Drug-Patents-and-Generics.aspx
Sabatini, Patricia. "EpiPen Furor Brings Protesters to Mylan's Headquarters." Pittsburgh Post-Gazette. N.p., n.d. Web. 16 Nov. 2016. http://www.post-gazette.com/business/healthcare-business/2016/08/30/EpiPen-furor-brings/stories/201608300158
Salazar, Heather. Case Manual. Accessed 13 Nov. 2016.
Salazar, Heather. Kantian Business Ethics. Accessed 13 Nov. 2016.
"Some Patients Forgo EpiPens Because They're Too Expensive." EMS1. N.p., n.d. Web. 16 Nov. 2016. http://www.ems1.com/epinephrine/articles/117785048-Some-patients-forgo-EpiPens-because-theyre-too-expensive/
Swetlitz, Ike. "Mylan Faces Two Potential Class Action Lawsuits over EpiPen Pricing." STAT. N.p., 30 Sept. 2016. Web. 16 Nov. 2016. https://www.statnews.com/2016/09/06/epipen-mylan-lawsuits/
Tuttle, Brad. "EpiPen Profits Are Much Higher Than What Mylan CEO Told Congress Last Week." Time. Time, n.d. Web. 16 Nov. 2016. http://time.com/money/4508037/epipen-profits-scandal-mylan-ceo-heather-bresch/
With the patent expiring soon, Mylan should consider an action plan that protects Mylan's future. The first and most important action Mylan should do is lower the price of the EpiPen. The next action should be to work with insurance companies to offer higher rebates and other deals to help pay for the medicine. Also, it would benefit Mylan to establish a donation of charity fund for the lower class who may not be able to afford EpiPens even at a reasonable price. Mylan absolutely has to reduce the price in order to pull themselves out of this dilemma. It was absurd for them to raise the price to such ridiculous levels in the first place and the population is acting accordingly. Also, when the patent ends, if they are still at their $600 price level as a cheaper generic enters the market, they will lose most of their market share. In regards to insurance companies, these are the businesses that Mylan relies on for a majority of their profit. The insurance company attempts to cover the cost up to a certain point. If Mylan can make a deal where the insurance companies pay more but buy in bulk and distribute to their clients, a mid-level price around $250 may be reasonable. Lastly, there will always be unfortunate families who require these tools but are too impoverished to buy it even at the original $124 price. Mylan can set up donations to help regain the trust of their longtime customers after years of scandal and dishonesty.
In order to prevent this from happening in the future, I think the introduction of competition will act as a natural barrier. Mylan was mainly only able to carry this out cause there were no consequences. The reason was to increase profit, and if they try this again with a generic on the market, then they will lose profit. Going forward, the only employee who should be penelized is Heather Bresch. Many have called for her to step down; this is a common move for a CEO to make after a scandal. Even if she does not want to step down, it becomes necessary for her to at least reduce her compensation by the 600% that she received for the price hikes; the company cannot endorse unethical behavior. Marketing becomes an important aspect when trying to fix ethical issues. The company has to issue a formal apology to its customers and promise to think about their well-being in the future. Mylan needs to try to regain the trust of patients. They can make deals with doctors to have them hand out brochures about the benefits of Mylan and the EpiPen. Mylan lost sight of the true reason they are a company: to promote the health of the population. With the actions and marketing plans being implemented, the company can grow and form a better ethical standard. They will regain the trust of their consumers and build stonger relationships while remaining profitable.Written By: Kanan Patel
References:
"Annual Report." Mylan N.V. -. N.p., n.d. Web. 16 Nov. 2016 http://apps.shareholder.com/sec/viewerContent.aspx?companyid=ABEA-2LQZGT&docid=11180036
"Mission Statement." Mylan- Seeing Is Believing. N.p., n.d. Web.
https://www.mylan.com/en/careers/life-at-mylan
Pollack, Andrew. "Mylan Raised EpiPen’s Price Before the Expected Arrival of a Generic." The New York Times. The New York Times, 25 Aug. 2016. Web. 16 Nov. 2016. http://www.nytimes.com/2016/08/25/business/mylan-raised-epipens-price-before-the-expected-arrival-of-a-generic.html?_r=0
Popken, Ben. "Mylan CEO Salary Rose by 600 Percent as EpiPen Price Rose 400 Percent." NBC News. N.p., n.d. Web. 16 Nov. 2016. http://www.nbcnews.com/business/consumer/mylan-execs-gave-themselves-raises-they-hiked-epipen-prices-n636591
"Reference for Business." Mylan Laboratories Inc. - Company Profile, Information, Business Description, History, Background Information on Mylan Laboratories Inc. N.p., n.d. Web. 16 Nov. 2016. http://www.referenceforbusiness.com/history2/71/Mylan-Laboratories-Inc.html
Robertson, Sally. "Drug Patents and Generic Pharmaceutical Drugs." News-Medical.net. N.p., 08 Sept. 2014. Web. 16 Nov. 2016. http://www.news-medical.net/health/Drug-Patents-and-Generics.aspx
Sabatini, Patricia. "EpiPen Furor Brings Protesters to Mylan's Headquarters." Pittsburgh Post-Gazette. N.p., n.d. Web. 16 Nov. 2016. http://www.post-gazette.com/business/healthcare-business/2016/08/30/EpiPen-furor-brings/stories/201608300158
Salazar, Heather. Case Manual. Accessed 13 Nov. 2016.
Salazar, Heather. Kantian Business Ethics. Accessed 13 Nov. 2016.
"Some Patients Forgo EpiPens Because They're Too Expensive." EMS1. N.p., n.d. Web. 16 Nov. 2016. http://www.ems1.com/epinephrine/articles/117785048-Some-patients-forgo-EpiPens-because-theyre-too-expensive/
Swetlitz, Ike. "Mylan Faces Two Potential Class Action Lawsuits over EpiPen Pricing." STAT. N.p., 30 Sept. 2016. Web. 16 Nov. 2016. https://www.statnews.com/2016/09/06/epipen-mylan-lawsuits/
Tuttle, Brad. "EpiPen Profits Are Much Higher Than What Mylan CEO Told Congress Last Week." Time. Time, n.d. Web. 16 Nov. 2016. http://time.com/money/4508037/epipen-profits-scandal-mylan-ceo-heather-bresch/
No comments:
Post a Comment